Monday 27 July 2009
Biotronics3D has worked with The Institute of Cancer Research (ICR) to develop and launch new software to significantly improve the accuracy of MRI scan analysis. Called 3D Net Perfusion, the system extracts data from images of tumours and transforms it into usable information.
A powerful analytical tool, 3D Net Perfusion enables clinicians to gain clearer comprehension of MRI scans, improving the accuracy of diagnosis and assessment of treatment efficacy. It is also an innovative way of visualising and measuring the blood supply to cancers – a crucial factor in tumour growth.
The software is the result of pioneering trials at the ICR led by Professor Martin Leach, David Collins and James d’Arcy, and is currently used in 10 research centres. Scientists from the ICR continue to work with Biotronics3D software developers to further enhance the product.
Paul Carnochan, Senior Business Development Manager at the ICR, believes the partnership could have broader implications and says: “London has an abundance of research capabilities and commercial expertise in the field of medical imaging and we believe that collaborations like this one can be the key to raising London’s profile as a major biotech hub.”
Harry Hatzakis, CEO of Biotronics 3D, says: “Innovation carries risks and in fast moving markets such as global diagnostics it is important to leverage skills that exist outside the company through partnerships such as ours with the ICR.”
The project has attracted significant investment from London-based venture specialist Longbow Capital LLP. Longbow’s co-founder Edward Rudd says: “Despite the potential gloom of 2008, now is the right time for investors to look to the future and support projects that exploit industry-academic collaborations with strong business plans for commercial markets.”
Ends
For more information please contact: Natalie Houston or phone 0207 093 0903
About The Institute of Cancer Research
The Institute of Cancer Research (ICR) is Europe’s leading cancer research centre with expert scientists working on cutting-edge research. In 2009, the ICR marks its 100 years of groundbreaking research into cancer prevention, diagnosis and treatment. In December 2008, the ICR was ranked as the UK’s leading academic research centre by the Times Higher Education’s Table of Excellence, based on the results of the Higher Education Funding Council’s Research Assessment Exercise. The ICR is a charity that relies on voluntary income. It is one of the world’s most cost-effective major cancer research organisations with more than 95p in every £ directly supporting research. For more information visit www.icr.ac.uk.
About Biotronics3D
Biotronics3D, headquartered in London, UK, develops and markets innovative software applications for the diagnostic imaging industry. The company provides cutting edge software technologies to improve healthcare by better extracting diagnostic data and transforming it into usable information available at the point-of-care. Biotronics3D Ltd is an EN ISO 13485:2003 certified company and its flagship product, 3Dnet Suite, has received FDA 510K market clearance and it is CE marked.For more information visit www.biotronics3d.com.